My SciELO
Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Archivos de la Sociedad Española de Oftalmología
Print version ISSN 0365-6691
Abstract
AMSELEM, L. et al. Intravitreal injection of Bevacizumab (Avastin®) for retinal angiomatous proliferation. Arch Soc Esp Oftalmol [online]. 2008, vol.83, n.1, pp.53-55. ISSN 0365-6691.
Clinical case: An 81-year-old man presented with stage 2 retinal angiomatous proliferation (RAP) as identified by fluorescein angiography and optical coherence tomography (OCT), and was shown to have a visual acuity (VA) of 20/40. One week after an intravitreal injection of bevacizumab (1.25 mg) the VA improved to 20/25, and the OCT showed a reduction of both intraretinal edema and pigment epithelium detachment. Three months after the injection, no ocular complications were observed, VA was 20/20 and the OCT showed an almost normal macular contour. Discussion: Intravitreal injection of bevacizumab may provide another treatment option for patients with RAP.
Keywords : Bevacizumab; intravitreal injection; retinal angiomatous proliferation; age-related macular degeneration; optical coherence tomography.